Caisse de depot et placement du Quebec Makes New Investment in Edwards Lifesciences Corporation $EW

Posted by Brenda Bartman on Aug 27th, 2026

Caisse de depot et placement du Quebec purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 967,537 shares of the medical research company’s stock, valued at approximately $87,523,000.

Other hedge funds also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences in the first quarter worth approximately $26,000. Finally, TrinityBridge Ltd purchased a new stake in Edwards Lifesciences during the second quarter worth $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $90.93 on Thursday. The company has a 50 day moving average price of $89.43 and a 200 day moving average price of $84.91. The firm has a market capitalization of $52.36 billion, a P/E ratio of 52.26, a PEG ratio of 2.38 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Citigroup raised their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, Royal Bank Of Canada boosted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Check Out Our Latest Research Report on EW

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.